Rejuvenate Biomed has commenced a Phase 2 clinical trial assessing its investigational compound, RJx-01, for treating muscle weakness and sarcopenia in patients with chronic obstructive pulmonary disease (COPD). The randomized, double-blind, placebo-controlled study involves 130 older adults who have been hospitalized due to severe acute exacerbations of COPD. The trial aims to evaluate the safety, tolerability, and efficacy of RJx-01 in maintaining muscle integrity and improving physical function in this patient population.
The study is a collaboration between Rejuvenate Biomed, the University of Leicester, the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC), and Wellcome Leap Inc. Dr. Neil Greening and Dr. Hamish McCauley from the NIHR Leicester BRC at University Hospitals of Leicester NHS Trust are leading the research.
Ann Beliën, CEO of Rejuvenate Biomed, expressed enthusiasm about the trial, stating that the company has received positive feedback from experts in sarcopenia and public health regarding RJx-01’s potential to not only slow progression but also restore muscle health in a way previously unseen.
The Dynamic Resilience program, co-funded by Wellcome Leap and Temasek Trust, is providing multimillion-dollar funding to support the study. Rejuvenate Biomed continues to seek engagement from strategic investors and partners who share its vision of transforming aging through science and innovation.
